Shanghai Obio Technology (Group) Corp., Ltd. (SHA:688238)

China · Delayed Price · Currency is CNY

6.72

+0.35 (5.49%)

Nov 5, 2026, 4:00 PM EST

SHA:688238 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	293.86	267.7	248.15	204.81	291.3	254.95
Revenue Growth	20.12%	7.88%	21.16%	-29.69%	14.26%	78.57%
Gross Profit	-17.5	-42.16	-102.92	-16.93	129.37	130.88
Operating Income	-201.25	-218.62	-279.92	-166.48	5.34	38.25
Net Income	-219.06	-235.06	-321.81	-127.94	39.26	54.26
Earnings Per Share	-0.35	-0.37	-0.50	-0.20	0.07	0.11
EPS Growth	-	-	-	-	-38.80%	-56.86%

Revenue by Segment

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Gene Therapy CRO Service	93.23
Gene Therapy CDMO Service	135.64
Regenerative Medicine Services	3.85
Biological Agents, Reagents and Others	34.7
Total	267.41

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	539.83	292.59	469.7	657.05	1,254	619.01
Total Debt	817.69	420.44	215.44	191.13	92	165.34
Net Cash (Debt)	-277.85	-127.85	254.27	465.92	1,162	453.67
Net Cash Growth	-	-	-45.43%	-59.90%	156.10%	-33.82%
Net Cash Per Share	-0.44	-0.20	0.39	0.72	1.92	0.89

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-78.42	-102.59	-61.07	-90.12	21.42	109.31
Capital Expenditures	-91.76	-126.24	-167.46	-547.12	-484.42	-262.11
Free Cash Flow	-170.18	-228.84	-228.53	-637.24	-462.99	-152.8
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-5.96%	-15.75%	-41.47%	-8.27%	44.41%	51.34%
Operating Margin	-68.49%	-81.67%	-112.80%	-81.29%	1.83%	15.00%
Pretax Margin	-74.69%	-87.07%	-125.98%	-75.98%	14.29%	23.84%
Profit Margin	-74.54%	-87.81%	-129.69%	-62.47%	13.48%	21.28%
FCF Margin	-57.91%	-85.48%	-92.09%	-311.15%	-158.94%	-59.94%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 6, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	-	239.46	-
Forward PE	-	132.36	132.36	137.88	81.09	-
PS Ratio	14.39	15.68	12.92	28.42	32.27	-